Brief Summary

COVID infection has resulted in multi-organ injury and may result in cardiovascular, pulmonary, neurological, and muscular damage. It is associated with significant asthenia and the long-term effects of the infection are still unclear, particularly for the development of pain and delayed functional rehabilitation. Glycomics "is the systematic study of the structure of glycans in a given cell type or organism. Glycans are complex oligosaccharides attached to proteins and lipids that regulate a variety of organic processes, including immunity Thus, glycans may influence different moments of the response to the virus and involved in the clinical severity of the disease, but may also change depending on the severity of symptoms and the organic response to SARS-CoV-2 infection. Glycomic data could provide important insights into interindividual differences at the molecular level that directly interact with SARS-CoV-2 and the development of mid- and long-term side effects. The ability to identify early those susceptible to developing COVID-19 infection and at higher risk for COVID-19 with unfavorable outcomes long after infection would help guide therapeutic strategy and provide important guidance for rational health care organization, which is of outmost importance. Long-term outcome data regarding post-COVID patient functional capacity and glycomics will be compared to assess whether there may be differences in protein glycosylation that may predict patient outcome.

Trial Health

On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment

374

participants targeted

Target at P75+ for all trials

Timeline

Completed

Started Mar 2021

Geographic Reach

1 country

1 active site

Status

completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

1.5 years study duration

Study Start

First participant enrolled

March 4, 2021

Completed

3 days until next milestone

First Submitted

Initial submission to the registry

March 7, 2021

Completed

2 days until next milestone

First Posted

Study publicly available on registry

March 9, 2021

Completed

6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 10, 2021

Completed

1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

September 10, 2022

Completed

Last Updated

April 4, 2023

Status Verified

March 1, 2023

Enrollment Period

6 months

First QC Date

March 7, 2021

Last Update Submit

March 30, 2023

Conditions

Chronic Pain Morbidity, Multiple Covid19

Outcome Measures

Primary Outcomes (1)

Glycomic profile as predictor of long-term morbidity
Analysis of total plasmatic and IgG glycans composition; analysis of IgG glycopeptides. Correlation with pain, severity of the disease and long-term functional rehabilitation
1 year